This page shows the latest Onpattro news and features for those working in and with pharma, biotech and healthcare.
for standard of care Onpattro (patisiran), Alnylam’s earlier RNAi ATTRv amyloidosis therapy that is administered intravenously every few weeks.
However, if approved, eplontersen will not have the ATTR market to itself and must compete with Pfizer’s Vyndaqel/Vyndamax (tafamidis) and Alnylam’s RNAi therapy Onpattro (patisiran).
Elsewhere in the therapy area is Alnylam’s Onpattro (patisiran), which received approval in hereditary ATTR amyloidosis (hATTR) in 2018. ... Onpattro is also currently being evaluated in a phase 3 study in ATTR amyloidosis with cardiomyopathy, with
Alnylam’s first RNAi drug – Onpattro (patisiran) for rare disease hereditary ATTR amyloidosis – has a similar pricing strategy. ... Onpattro, on the other hand, launched with a $450, 000 per year price tag, and subsequently dropped to $345, 000
In the ATTR polyneuropathy indication it has competition from Alnylam’s injectable drugs Onpattro (patisiran) and Ionis’ Tegsedi (inotersen), which were approved for that use in Europe in 2018.
If approved, lumasiran would be Alnylam’s third RNAi drug after Onpattro (patisiran) for polyneuropathy in rare disease hereditary ATTR amyloidosis, which was cleared by the FDA in 2018, and Givlaari
More from news
Approximately 7 fully matching, plus 15 partially matching documents found.
Onpattro was approved to treat adults with the. destruction of nerves that results from a rare disease, hereditary transthyretin- mediated (hATTR) amyloidosis, and was launched with a $450, 000 per year ... The company has tried to be creative with its
Alnylam's Theresa Heggie. Alnylam and its extraordinary ‘gene silencing’ technology is making its debut in Europe with the launch of Onpattro. ... PME talks to its European leader Theresa Heggie. Even as it launches its first ever product Onpattro,
More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.
No results were found
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...